A method of forming an implant in the tissue can include: providing an injectable composition having a neat liquid carrier, wherein the neat liquid carrier is substantially liquid at room temperature and/or about body temperature; and injecting the neat liquid solution into the tissue at the rate of 10-12000 injections per minute and/or at an amount of 1.0E-02 ml to 1.0E-16 ml per needle per injection. The neat liquid carrier can be polymeric or non-polymeric. The neat liquid carrier can be biodegradable. The neat liquid carrier can include a viscosity-modifying agent. The injecting can form an implant with area greater than or equal to 5 mm.sup.2. The neat liquid carrier can be injected at a depth of 10 microns to 5 mm. The neat liquid solution can include a drug or other agent.

An apparatus and method for depositing a particulate containing composition onto mammalian skin such that when the particles contact the mammalian skin they have a momentum defined by ρvr, which is within the range of about 0.1 kg/ms≦ρvr≦about 12.0 kg/ms. The particles can be in the range of from about 10 nanometers to about 10 micrometers, in size. And the particles may be selected from the group consisting of titanium dioxide, zinc oxide, iron oxide, polyethylene, polypropylene, polyethylene terephthalate, polycarbonate, polyvinyl chloride, glass, silica and mixtures thereof. The particles are imbedded below the first layer of dead skin cells in the stratum corneum but they do not pass all the way through the stratum corneum into the living cells of the epidermis or dermis layers of the skin.

Provided is an applicator for the dispensing of a powder such as a pharmaceutical powder, on a target location. Also, provided are methods of applying a powder on a surface using the applicator.

An accelerator module is connected to an initiator module and generates supersonic waves from subsonic waves generated by the initiator module. The supersonic waves deliver particles to cells in tissues. The accelerator module may include a knocking-detonation transition metal and a detonation material. An example of the knocking-detonation transition metal is copper (I) 5-nitrotetrazolate. Another example of the knocking-detonation transition metal is lead azide. An example of the detonation material is pentaerythritol tetranitrate (PETN).

The invention relates generally to methods and systems for the treatment of pelvic tissues using a high pressure injection device to deliver a therapeutic composition that includes a large molecule therapeutic agent, such as a nucleic acid or a polypeptide, to a target tissue in the pelvic area. Methods of the invention can improve delivery of the therapeutic agent into the tissue, which can be beneficial for the treatment of a pelvic tissue disorder, such as bladder and prostate tumors.

A pyrotechnic drive device includes a housing (3) provided with a combustion chamber (5) having pyrotechnic material (15) as well as an activation device (13). The combustion chamber is delimited at least in an initial state on all sides by combustion chamber walls (3, 7, 13, 17, 33, 35) formed in at least one partial region by respective pressure-receiving surface or respective pressure-receiving element (17, 35). Each pressure-receiving impact of a pressure-receiving element (17, 35) is impacted after the activation of the pyrotechnic material (15) in such a way by the gas pressure generated in this manner that the pressure-receiving element (17, 35) is moved and/or deformed (17, 35) and/or a mechanical impulse is thus transmitted via the pressure-receiving element (17, 35) to an element to be driven (19) so that a connected substance (25) is transmitted. The residual volume of the combustion chamber (5), in which no pyrotechnic material (15) is provided in the initial state, is filled with a liquid, a gel-like or pasty filling material (21), and/or a soft, rubber-like material.

This invention provide novel compositions, methods and devices for sustained drug delivery. The compositions can include a fluid carrier; a plurality of first polymeric microparticles having a bioactive agent dispersed in the fluid carrier; and a plurality of second polymeric microparticles having a visualization agent dispersed in the fluid carrier with the first microparticles. Alternative compositions can include: a fluid carrier; and a plurality of polymeric microparticles having a bioactive agent encapsulated therein and a visualization agent on a surface of the polymeric microparticles, the plurality of polymeric microparticles being dispersed in the fluid carrier. The microencapsulated sustained drug delivery compositions are deposited using oscillating needle apparatus oscillating at 10-12000 minutes per minutes at an amount of 1.0E-03 mL to 1.0E-16 mL per injection.

The invention relates to a needleless injection device, comprising a firing chamber (11) for the needleless injection of a substance (25), having a firing chamber containing a pyrotechnic material and a gel-like medium, with which a substance, in particular an active substance, can be accelerated at high speed and injected in a needleless manner into a tissue or into a body by means of a membrane (15).

The invention also relates to a method for producing a needleless injection device of this type containing a firing chamber together with pyrotechnic material and filled with a gel-like medium, and use thereof.

The invention relates to a needleless injection device, containing at least one membrane, or a corresponding device for needleless injection of a substance, having at least one membrane, with which a powdered, gel-like or liquid agent, in particular an active agent, can be injected in a needleless manner into a tissue or a body by means of high impact speed. The invention also relates to a method for such a needleless injection device containing a membrane, and use thereof.

A device for delivery of particles into biological tissue includes at least one conduit and a propellant source fluidically coupled to the conduit and configured to deliver a propellant into the conduit. A particle source is configured to release elongated particles into the conduit, the elongated particles having a width, w, a length, l>w. The propellant source and the conduit are configured to propel the elongated particles in a collimated particle stream toward the biological tissue. An alignment mechanism is configured to align a longitudinal axis of the elongated particles to be substantially parallel to a direction of the particle stream in an alignment region of the conduit. The aligned elongated particles are ejected from the conduit and impact the biological tissue.